Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial-Reference-Cited by-同舟云学术

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

Published:2010-10-13 Issue:2 Volume:107 Page:214-219
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Bracarda Sergio,Bellmunt Joaquim,Melichar Bohuslav,Négrier Sylvie,Bajetta Emilio,Ravaud Alain,Sneller Vesna,Escudier Bernard

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2010.09707.x/fullpdf

Reference42 articles.

1. Molecular-genetic investigation of sporadic renal-cell carcinoma - analysis of allele loss on chromosomes 3P, 5Q, 11P, 17 and 22;Foster;Br J Cancer,1994

2. Mutations of the VHL tumor-suppressor gene in renal-carcinoma;Gnarra;Nat Genet,1994

3. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal-carcinoma;Herman;Proc Natl Acad Sci USA,1994

4. VEGF-targeted therapy in metastatic renal cell carcinoma;Rini;Oncologist,2005

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term Outcome With Prolonged Use of Interferon-alpha Administered Intermittently for Metastatic Renal Cell Carcinoma: A Phase II Study;Anticancer Research;2023-05-29

2. Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis;Journal of Oncology;2023-02-08

3. Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer;Neoplasia;2022-10

4. Evaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinoma;Oncology in Clinical Practice;2022-08-31

5. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study);Oncology Research and Treatment;2022